VERTEX RESTRICTIONS ON NOMINATION AND DEVELOPMENT. So long as NOVARTIS is using commercially reasonable efforts with respect to the development of a particular Drug Product Candidate or the commercialization of a particular Drug Product, VERTEX will not (i) propose a Compound for development under the License Agreement which is a Back-up Compound with respect to that Drug Product Candidate or Drug Product, or (ii) until after the period starting on the date on which NOVARTIS has exercised its Development Election for a particular Drug Product Candidate and ending [***] (the "Lead Period"), commence development of that Back-up Compound either directly or together with or through an Affiliate or a Third Party.
Appears in 2 contracts
Samples: And Early Development Agreement (Vertex Pharmaceuticals Inc / Ma), Confidential Treatment (Vertex Pharmaceuticals Inc / Ma)
VERTEX RESTRICTIONS ON NOMINATION AND DEVELOPMENT. So long as NOVARTIS is using commercially reasonable efforts with respect to the development of a particular Drug Product Candidate or the commercialization of a particular Drug Product, pursuant to Sections 3.6 and 5.6 hereof, VERTEX will not (i) propose a Compound for development under the License Agreement which is a Back-up Compound with respect to that Drug Product Candidate or Drug Product, or (ii) until after the period starting on the date on which NOVARTIS has exercised its Development Election for a particular Drug Product Candidate and ending [***] (the "Lead Period"), commence development of that Back-up Compound either directly or together with or through an Affiliate or a Third Party.
Appears in 2 contracts
Samples: And Early Development Agreement (Vertex Pharmaceuticals Inc / Ma), Confidential Treatment (Vertex Pharmaceuticals Inc / Ma)